Nirsevimab is a monoclonal antibody crucial for preventing severe RSV in infants and young children. A nationwide shortage prompted a revised allocation strategy prioritizing VFC-eligible infants in ...

Palivizumab-eligible infants under the age of 1 year who had been born prematurely (gestational age, ≤35 weeks) or who had chronic lung disease of prematurity or hemodynamically significant congenital ...

A new study led by researchers at National Jewish Health has revealed that, while a wide range of viruses can cause lower respiratory tract illnesses (LRIs) in infants, certain viruses and viral ...

The Lancet Child & Adolescent Health: Monoclonal antibody nirsevimab provides strong real-world protection against severe RSV in infants, suggests meta-analysis Nirsevimab, a monoclonal antibody, is ...

The researchers found that the median age of those admitted to the ICU was 1.9 months, and only 41.3% had an underlying comorbidity. HealthDay News — Comorbidities are seen less often in severe ...

DENVER -- A new study led by researchers at National Jewish Health has revealed that, while a wide range of viruses can cause lower respiratory tract illnesses (LRIs) in infants, certain viruses and ...